Corbus Pharmaceuticals (CRBP) announced that data from its US and UK conducted first-in-human dose escalation clinical study of CRB-701 is ...

Corbus Pharmaceuticals announced results from its first-in-human dose escalation study of CRB-701, presented at the ASCO GU 2025 conference. This Phase 1 study assessed the efficacy and safety of ...

(RTTNews) - Corbus Pharmaceuticals Holdings, Inc.(CRBP), has reported promising data for CRB-701 or SYS6002, a next-generation Nectin-4 targeting antibody-drug conjugate or ADC, at the 2025 ...

Corbus Pharmaceuticals presented Phase 1 data on CRB-701 at ASCO GU, showing safety, tolerability, and responses across multiple tumor types.

Corbus Pharmaceuticals presented new data from the first Western study of its antibody-drug conjugate treatment for cancer.

Corbus earlier announced the presentation of data from its US and UK conducted first-in-human dose escalation clinical study of CRB-701 (SYS6002) at the 2025 American Society of Clinical Oncology ...

Corbus Pharmaceuticals (CRBP) stock drops 12% after mixed Phase 1 trial results for its lead cancer candidate. Read more here.

CRB-701 shows 4% combined peripheral neuropathy rate across studies, with no dose-limiting toxicities reported in the dose escalation phase. A proactive ocular toxicity protocol in the Western ...

CRB-701 demonstrated a longer ADC half-life and lower free-MMAE exposure relative to enfortumab vedotin (EV). Responses were observed in several tumor types, including previously unexplored HNSCC ...

Citing safety data, the company said CRB-701, a nectin-4 targeting antibody drug conjugate was well tolerated in the Phase 1 trial with majority of treatment emergent adverse events being grade 1 ...